Application of astragalus polysaccharide as potential prebiotics in preparation of medicine for preventing and / or treating ulcerative colitis
By preparing Astragalus polysaccharides with molecular weight ≤50KDa, using their fermentation characteristics in the colon, the application of Astragalus polysaccharides in the treatment of ulcerative colitis was solved, significantly improving the symptoms of colitis and intestinal health, and protecting the intestinal mucus barrier.
Patent Information
- Application Number
- CN202410190009.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-02-20
AI Technical Summary
The identification of specific components in Astragalus polysaccharides and their development as potential prebiotics are lacking in existing studies, especially in the treatment of ulcerative colitis, and Astragalus polysaccharides of different molecular weights have different effects in improving the symptoms and damage of colitis. .
Through water extraction, alcohol precipitation, enzymatic decomposition, ultrafiltration and vacuum freeze-drying, astragalus polysaccharides with molecular weight ≤50KDa, these polysaccharides with specific molecular weights are selectively fermented by Lactobacillus and Bifidobacterium in the colon, affecting the intestine The microbiota is composed of which promotes the growth of beneficial bacteria, reduces the disease activity index, and protects the intestinal mucus barrier.
Astragalus polysaccharides of different molecular weights have prebiotic characteristics in the colon, improve the symptoms and damage of colitis, reduce the disease activity index, protect the intestinal mucus barrier, and significantly improve the clinical manifestations of ulcerative colitis.
Smart Images

Figure CN119015302A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to the use of astragalus polysaccharide as a potential prebiotic in the preparation of a medicine for preventing and / or treating ulcerative colitis. Background Art
[0002] As a key bioactive substance, dietary polysaccharides are also one of the important sources of prebiotics. Dietary polysaccharides are not only an important energy source for the cecal and colonic microbiota, but also can mediate specific regulation of the intestinal microbiota and confer health benefits. These dietary prebiotics are believed to improve intestinal health, help reduce weight, treat type 2 diabetes, and inhibit non-alcoholic steatohepatitis. More and more studies have confirmed that the beneficial effects of prebiotics depend on the intestinal flora. Current studies have emphasized the efficacy of polysaccharides from various sources (including chitosan, seaweed polysaccharides, and polysaccharides extracted from fungi, bacteria, and traditional Chinese medicine) in preventing or alleviating colitis. Among them, the strong potential of plant polysaccharides in the treatment of colitis is particularly worthy of attention. These polysaccharides have the characteristics of high efficiency, low toxicity, and natural sources. They also have anti-inflammatory, antioxidant, and immunomodulatory properties, and play an important role in maintaining the integrity of the intestinal mucosal barrier. Therefore, it is of great significance to find a new type of dietary polysaccharide from plants and explore its beneficial properties.
[0003] Astragalus is a highly respected herb in traditional Chinese medicine with a long history of clinical application. It can be used as a food as well as a medicine to improve and treat various diseases. Among the various components such as flavonoids, saponins, and alkaloids, astragalus polysaccharides (APS) are the most important bioactive components. APS is well known for its wide range of pharmacological effects, including immunomodulatory, anti-aging, anti-tumor, and antiviral properties, which have been confirmed in previous studies. However, most studies have focused on the overall effects of total APS and ignored the identification of specific components that produce these therapeutic effects. There is also a lack of comprehensive research to determine which specific components of APS have prebiotic properties and which specific parts of APS can be developed as potential prebiotics. Therefore, studying and identifying the specific parts of APS with prebiotic potential can not only deepen the understanding of the functional components of APS, but also pave the way for the development of APS prebiotic therapy. Summary of the invention
[0004] The object of the present invention is to provide an application of astragalus polysaccharide as a potential prebiotic in the preparation of a medicament for preventing and / or treating ulcerative colitis.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides an application of astragalus polysaccharide as a potential prebiotic in the preparation of a medicament for preventing and / or treating ulcerative colitis, characterized in that the molecular weight of the astragalus polysaccharide is ≤50KDa.
[0007] Preferably, the molecular weight of the astragalus polysaccharide is less than 10 KDa.
[0008] Preferably, the preparation method of astragalus polysaccharide comprises the following steps:
[0009] (1) Soaking the astragalus powder in water, boiling and extracting, and obtaining an extract;
[0010] (2) concentrating and cooling the extract, adding anhydrous ethanol, and performing alcohol precipitation to obtain an extract;
[0011] (3) dissolving the precipitate in water, removing protein from the sample by enzymatic hydrolysis combined with Sevage method, and collecting the supernatant;
[0012] (4) adding anhydrous ethanol to the supernatant, collecting the precipitate and performing vacuum freeze drying to obtain crude astragalus polysaccharide;
[0013] (5) Dissolving crude astragalus polysaccharide in water to obtain a crude astragalus polysaccharide aqueous solution, and ultrafiltration of the crude astragalus polysaccharide aqueous solution; the ultrafiltration cutoff value is 50 KDa and 10 KDa; and collecting the fractions with molecular weight <10 KDa and 10 KDa ≤ molecular weight ≤50 KDa.
[0014] Preferably, the water content of the astragalus powder is 35% to 75%, and the particle size is less than 50 mesh; the mass volume ratio of the astragalus powder to water is 1g:15-25mL, and the soaking time is 12-24h; the extraction is performed 2 to 4 times, and the extraction time each time is 1 to 1.5h.
[0015] Preferably, the concentration in step (2) is to concentrate to 1 / 2 to 1 / 3 of the original volume, and the concentration temperature is 90 to 100°C.
[0016] Preferably, the amount of water added in step (3) is based on completely dissolving the precipitate; the enzymatic hydrolysis method uses papain, and the enzymatic activity of the papain is 100,000 U / g; the amount of papain added is 1-3 (w / v)%; the temperature of the enzymatic hydrolysis is 55-65°C, and the time is 4-6h.
[0017] Preferably, the final concentration of the anhydrous ethanol after addition in step (2) and step (4) is 75-85 (v / v)%, the temperature of the alcohol precipitation is 1-4°C, and the time is 12-16 hours.
[0018] Preferably, the vacuum freeze-drying in step (4) is carried out at a temperature of -70 to -80°C, a vacuum degree of 10 MPa, and a time of 20 to 24 hours.
[0019] Preferably, the concentration of the crude astragalus polysaccharide aqueous solution in step (5) is 200-300 g / L.
[0020] The present invention has the following beneficial effects:
[0021] The present invention performs water extraction, alcohol precipitation, protein removal and concentration on Astragalus to obtain crude Astragalus polysaccharide; the crude Astragalus polysaccharide is then ultrafiltered, concentrated and vacuum freeze-dried to finally obtain Astragalus polysaccharide with a molecular weight of ≤50KDa. The present invention proves through experiments that not all Astragalus polysaccharides with molecular weights can be used as prebiotics, and Astragalus polysaccharides with different molecular weights have different effects in improving colitis symptoms and colon damage. The Astragalus polysaccharide with a molecular weight of ≤50KDa obtained in the present invention is not easily degraded by human digestive juice, can be selectively fermented by lactobacillus and bifidobacterium in the colon, has the characteristics of a prebiotic, can also affect the composition of microbiota in the intestine, promote the growth of beneficial bacteria, and can reduce the disease activity index score, inhibit the shortening of colon length, protect the intestinal mucus barrier, and better improve colitis symptoms and colon damage. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is the standard reference spectrum of 16 monosaccharides in Example 2;
[0023] Figure 2 The monosaccharide composition of Astragalus polysaccharide in Example 2 is determined;
[0024] Figure 3 The results of the determination of the molecular weight distribution of Astragalus polysaccharide APS in Example 2;
[0025] Figure 4 The microstructure of APS and the other two components in Example 4 were measured by scanning electron microscopy.
[0026] Figure 5 The proliferation of probiotics in different carbon sources in Example 6;
[0027] Figure 6 The pH changes of the probiotics in Example 6 during their growth on different carbon sources;
[0028] Figure 7 The effects of APS and the other two components on the bacterial community structure in Example 7;
[0029] Figure 8 The regulation of APS and the other two components on bacteria at the phylum level in Example 7;
[0030] Fig. 9 The regulation of APS and the other two components on bacteria at the genus level in Example 7;
[0031] Fig.10 Identification of species differences between different groups during in vitro colonic fermentation in Example 7;
[0032] Fig.11 The effects of APS and the other two components on intestinal SCFA levels in Example 7;
[0033] Fig.12 The dynamic distribution of APS-1 and APS-2 in mice in Example 8;
[0034] Fig.13 The distribution of APS-1 and APS-2 in the mouse intestine in Example 8;
[0035] Fig.14 This is the design diagram of the animal experiment in Example 9;
[0036] Fig.15 The effect of APS-1 and APS-2 on the body weight of DSS-induced colitis mice in Example 9;
[0037] Fig.16 The effect of APS-1 and APS-2 on the colon length of DSS-induced colitis mice in Example 9;
[0038] Fig.17 The effect of APS-1 and APS-2 on the DAI index score of DSS-induced colitis mice in Example 9;
[0039] Fig.18 The effects of APS-1 and APS-2 on the inflammation level of colitis mice in Example 10;
[0040] Fig.19 The effects of APS-1 and APS-2 on the intestinal barrier function of mice with ulcerative colitis in Example 11;
[0041] Fig. 20 The diagram is a diagram of the bacterial flora imbalance (α diversity) caused by APS-1 and APS-2 regulating DSS induction in Example 12, the left diagram is a Simpson index diagram, and the right diagram is a Shannon index diagram;
[0042] Fig.21 This is a diagram of bacterial flora imbalance (β diversity) caused by APS-1 and APS-2 regulating DSS induction in Example 12;
[0043] Fig. 22APS-1 and APS-2 repaired the intestinal flora structure (genus level) damaged by DSS in Example 12;
[0044] Fig.23 APS-1 and APS-2 in Example 12 repaired the intestinal flora structure (species level) damaged by DSS;
[0045] Fig.24 This is a graph showing the content of short-chain fatty acids in the intestine of mice in Example 13. DETAILED DESCRIPTION
[0046] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0047] Example 1
[0048] Extraction and separation of astragalus polysaccharides
[0049] (1) Water extraction and concentration, alcohol precipitation
[0050] Take an appropriate amount of astragalus purchased from Gansu, China, dry it to a water content of 35% to 75%, grind it and pass it through a 50-mesh sieve. Take 100g of astragalus powder and soak it in 2L of distilled water for 24 hours, then extract it with distilled water in a boiling water bath for 3 times, each time for 1 hour, to obtain an extract.
[0051] The extract was concentrated to 1 / 3 of the original volume and cooled to room temperature (25° C.) Then, anhydrous ethanol was added to the extract until the concentration of ethanol reached 80% (v / v), and the extract was placed in a 4° C. refrigerator for incubation overnight.
[0052] (2) Protein removal
[0053] The extract after standing was centrifuged at 4500 rpm for 10 min to collect the precipitate; the precipitate was dissolved in water, and the amount of water added was based on the complete dissolution of the precipitate to obtain an aqueous solution, to which 2 (w / v)% of papain with an enzyme activity of 100,000 U / g was added, and the reaction was carried out at 60°C for 5 h.
[0054] Take 4 mL of the solution after the reaction and mix it with 1 mL of chloroform-n-butanol solution, place it in a test tube and shake it thoroughly for 30 minutes, then centrifuge it for 1 minute, and then separate the aqueous phase from the chloroform phase. Add chloroform-n-butanol solution equivalent to 1 / 4 of its volume to the aqueous phase, and repeat the above process three times.
[0055] (3) Secondary precipitation
[0056] The aqueous phase in the previous step was centrifuged at 4500 rpm for 15 min, the supernatant was taken, anhydrous ethanol was added to the supernatant to a final alcohol concentration of 80 (v / v)%, and the mixture was allowed to stand overnight to take the precipitate. The precipitate was dried at -80°C and a vacuum degree of 10 MPa for 24 h to obtain crude astragalus polysaccharide APS.
[0057] Example 2
[0058] APS molecular weight determination and monosaccharide composition determination
[0059] 5 mg of APS obtained in Example 1 was mixed with 2 mL of 3 mol / L trifluoroacetic acid solution in an ampoule and hydrolyzed at 120°C for 3 h. The acid hydrolysis solution in the tube was blown dry with nitrogen, 5 mL of deionized water was added and vortexed to mix, 50 μL was drawn and added to 950 μL of deionized water, and centrifuged at 12000 rpm for 5 min. The supernatant was analyzed for monosaccharide composition on an ICS5000 ion chromatograph (Thermo Fisher, USA). All monosaccharide standard solutions were accurately mixed as a mixed standard ( Figure 1 ). According to the absolute quantification method, the mass of different monosaccharides was determined, and the molar ratio was calculated based on the molar mass of the monosaccharides. TM The PA20 (3×150 mm) column was used to detect monosaccharides at 0. The electrochemical detector had a flow rate of 3 mL / min and a temperature of 30° C. The mobile phases were A: H2O, B: 15 mmol / L NaOH, and C: 15 mmol / L NaOH and 100 mmol / L NaOAc.
[0060] The monosaccharide composition of APS is shown in Figure 2 As shown, it was found that Astragalus polysaccharide contained glucose, arabinose and galactose with a molar ratio of 0.853:0.070:0.077.
[0061] The molecular weight of the APS obtained in Example 1 was determined using high performance gel permeation chromatography (HPGPC, polymer laboratories, UK) using a size exclusion chromatography column equipped with an ultraviolet detector (UVD) and a refractive index detector (RID). Ultrapure water was used as the mobile phase at a flow rate of 0.5 mL / min. The average molecular weight of the polysaccharide was calculated based on a calibration curve established based on a series of dextran with known molecular weights.
[0062] The results of the APS molecular weight distribution in Example 1 are as follows Figure 3 As shown, Figure 3 The red line in the middle is the standard curve of the dextran standard, the blue line is the curve of the astragalus polysaccharide sample, and the data on the chromatographic peak are the average molecular weight (MW) of each cut part. Figure 3The peak fluctuations of Astragalus polysaccharide were cut into three parts. The MW of the first part was greater than 400 KDa, the molecular weight of the second part was about 20 KDa, and the molecular weight of the third part was about 2000 Da. Based on the results of the molecular weight distribution of Astragalus polysaccharide, Astragalus polysaccharide was ultrafiltered.
[0063] Example 3
[0064] Separation of Astragalus Polysaccharides by Ultrafiltration
[0065] 10 g of the crude astragalus polysaccharide obtained in Example 1 was redissolved in 50 mL of distilled water, and after pretreatment through a membrane with a pore size of 0.45 μm, the sample was ultrafiltered using membranes with cutoff values of 50 KDa and 10 KDa.
[0066] The fractions retained and filtered from each membrane were collected, and the extract was concentrated to 1 / 3 of the original volume, and dried at -80°C and 10 MPa vacuum for 24 hours. Finally, two molecular weights of astragalus polysaccharides APS-1 (<10 KDa) and APS-2 (10-50 KDa) were obtained.
[0067] Example 4
[0068] Structural Analysis of Astragalus Polysaccharide
[0069] The astragalus polysaccharide APS obtained in Example 1 and the APS-1 and APS-2 obtained in Example 3 were placed on a scanning electron microscope sample stage and analyzed using an Apreo S scanning electron microscope (SEM, Thermo Fisher Scientific). A trace amount of polysaccharide sample was evenly dispersed on the surface of the sample holder and observed by secondary electron signal imaging.
[0070] Previous studies by the inventors have shown that the conditions of extraction and preparation can affect the structural properties, activity and surface morphology of polysaccharide compounds. This example uses scanning electron microscopy as an effective tool for observing changes in the surface morphology of polysaccharides, which helps to understand the microstructure of different polysaccharides. Figure 4 It can be seen that the microstructure of the original APS presents an irregular spherical shape with many depressions on the surface. After ultrafiltration treatment, it was found that the shapes and surfaces of the polysaccharide components APS-1 and APS-2 with different molecular weights showed obvious changes, and both turned into irregular fragments. APS-1 presents a small flake structure with a rough surface and many honeycomb holes; APS-2 presents a relatively flat and smooth surface. In contrast, the microstructure of APS is different from that of the other two samples, indicating that ultrafiltration may lead to differences in microstructural morphology, or that polysaccharides of different molecular weights themselves have different morphologies.
[0071] Example 5
[0072] In vitro simulated digestion
[0073] Take 20mL of simulated saliva (SSF) and preheat it to 37℃, add 20mL of 10.0mg / mL APS solution, and keep the α-amylase activity in the total system at 5000U / mL, adjust the pH to 7 with 0.1M dilute hydrochloric acid, heat in a 37℃ water bath, and take 1mL at 0h, 0.5h, 1h, and 2h respectively. After sampling, use a boiling water bath to inactivate, centrifuge at 3000rpm and 4℃ for 10min, and determine the reducing sugar content in the supernatant by 3,5-dinitrosalicylic acid (DNS) method. Take 20mL of simulated gastric fluid (SGF) and preheat it at 37℃, add 20mL of saliva simulated digestive fluid from the previous stage, 35.4mg of pepsin and 37.5mg of gastric lipase to the total system, use 1M HCl to adjust the pH to 3.0, heat in a 37℃ water bath, take 1mL of samples at 0h, 0.5h, 1h, 2h, 4h, and 6h, respectively, inactivate in a boiling water bath after sampling, centrifuge at 3000rpm and 4℃ for 10min, and determine the reducing sugar content in the supernatant by 3,5-dinitrosalicylic acid (DNS) method. In 25 mL of simulated intestinal fluid (SIES), 50 mL of 7% pancreatic enzyme, 100 mL of 4% bile salt and 6.5 mg of trypsin were added to prepare enzyme-containing simulated intestinal fluid. Then 6 mL of enzyme-containing simulated intestinal fluid was added to 20 mL of gastric juice simulated digestive fluid that had completed the reaction in the previous stage. 1 M NaHCO3 was added to adjust the pH to 7. The mixture was heated in a water bath at 37°C. 1 ml of samples were taken at 0 h, 0.5 h, 1 h, 2 h, 4 h and 6 h respectively. After sampling, the mixture was inactivated in a boiling water bath. The mixture was centrifuged at 3000 rpm and 4°C for 10 min. The reducing sugar content in the supernatant was determined by 3,5-dinitrosalicylic acid (DNS) method.
[0074] Table 1 Changes in reducing sugar content of APS, APS-1 and APS-2 during in vitro simulated digestion
[0075]
[0076]
[0077] Note: The values are mean ± standard deviation. Different superscript lowercase letters in each row indicate significance (p ≤ 0.05).
[0078] As shown in Table 1, the reducing sugar content of the APS-1 group did not change significantly during the digestion of saliva, gastric juice and small intestinal juice, that is, APS-1 remained stable; the reducing sugar content of the APS group increased during the digestion of gastric juice and small intestinal juice, that is, APS was partially degraded; the reducing sugar content of the APS-2 group did not change significantly during the digestion of saliva and gastric juice, and APS-2 was only slightly degraded by saliva and gastric juice. Studies have reported that dietary fiber is not degraded by human digestive juices, but only by intestinal microorganisms in the intestine. Therefore, APS-1 and APS-2 have the characteristics of prebiotics.
[0079] Example 6
[0080] Astragalus polysaccharide as the only carbon source for pure culture of standard probiotics
[0081] Seven probiotics (Bifidobacterium breve ATCC 15700, Bifidobacterium longum ATCC 15707, Bifidobacterium adolescentis ATCC 15703, Pediococcus acidilactici ATCC 25742, Lactobacillus casei ATCC 393, Lactobacillus rhamnosus ATCC 5103, Lactobacillus acidophilus ATCC 4536) were activated three times in an anaerobic chamber (GENE SCIENCE E200plus, USA) at 37°C under an atmosphere of 80% N2, 10% H2 and 10% CO2. Four experimental groups were set up, and the culture medium was supplemented with APS, APS-1, APS-2, and inulin as the sole carbon source, respectively. A blank control group without carbon source was set up at the same time. The culture medium of the five groups contained 2.0 g peptone, 2.0 g yeast extract powder, 0.1 g NaCl, 0.04 g KH2PO4, 0.04 g K2HPO4, 0.01 g CaCl2·2H2O, 0.01 g MgSO4, 0.01 g MgSO4·7H2O, 2.0 g NaHCO3, 0.5 g L-cysteine hydrochloride, 0.5 g bile salt, 2 mL / L Tween 80 and 10 μL vitamin K1, with a pH of 7.0 and a final concentration of 10 g·L -1 .
[0082] The activated strains were placed in culture medium and cultured in an anaerobic chamber at 37°C for 48 h. Samples were collected from each bottle at 0, 6, 12, 24, 36 and 48 h for further analysis.
[0083] Depend on Figure 5It can be seen that in the absence of carbon source MRS broth medium, no probiotics grew significantly. However, they can grow at different fixed biomass and growth rates in the presence of APS, APS-1, APS-2 or inulin. Bifidobacterium breve, Bifidobacterium longum, Lactobacillus rhamnosus, and Lactobacillus acidophilus are better than inulin when APS-1 and APS-2 are used as carbon sources. The growth-promoting effect of APS-1 on Pediococcus acidilactici is comparable to that of inulin. At the same time, we observed that APS-1 and the other two components could not be quickly utilized by Lactobacillus casei compared with inulin, but in the later stage, APS-1 and APS-2 could be observed to have a good promoting effect on Lactobacillus casei. These results indicate that APS-1 and APS-2 may act as a new type of prebiotic.
[0084] The growth of probiotics is accompanied by changes in pH, which can reflect their metabolic activity. Figure 6 It can be seen that the pH value also decreased significantly with the growth of probiotics. Related studies have shown that the decrease in fermentation pH is attributed to the growth of bacteria and the accumulation of metabolites acetate, propionate, butyrate and lactic acid. Therefore, the decrease in pH during the growth of APS-1 and APS-2 as the only carbon source for probiotics may be related to the acid-producing metabolites of probiotics.
[0085] Example 7
[0086] Colonic fermentation of astragalus polysaccharide
[0087] Fresh human feces were used for in vitro fermentation of APS. Fresh fecal samples were collected from two healthy female volunteers and two healthy male volunteers, aged between 22 and 30 years old, with normal BMI, who had not received antibiotic treatment within 6 months before participating in this study and had no history of gastrointestinal diseases. After collection, the fecal samples were immediately stored under hypoxic conditions, suspended in 50mM sterile phosphate buffered saline with a pH of 7.2 at a ratio of 1:9 (w / v), homogenized for 10 minutes, and centrifuged at 4000rpm to collect the supernatant to obtain fecal slurry. 5.0mL of 10% fecal slurry was added to 45mL of basal culture medium (such as the culture medium in Example 6 above) containing APS, APS-1, APS-2, and inulin (positive control), respectively, and placed in an anaerobic chamber for fermentation at 37°C for 48h. The blank group was a culture medium without the addition of a carbon source.
[0088] The Chao1 index is usually used to estimate the total number of species. The Simpson and Shannon indices are often used to evaluate the diversity of microorganisms in samples. The larger the value, the higher the community diversity. Figure 7It can be seen that after 12 hours of in vitro fermentation, the Chao index of the APS group, APS-1 group, APS-2 group and inulin group was significantly lower than that of the control group. The Simpson and Shannon indexes also confirmed that the uniformity and diversity of the microbiota were reduced to varying degrees, indicating that the addition of APS, APS-1, APS-2 and inulin affected the diversity of the intestinal microbiota.
[0089] The inventors also studied the effects of adding different dietary fibers on the composition of the intestinal microbiota in the stool samples of this example. The microbial regulatory effects of APS, APS-1, APS-2, and inulin were evaluated at the phylum and genus levels. Figure 8 As shown in the figure, the main phyla observed in each group are Proteobacteria, Firmicutes, and Actinobacteria. However, the blank group has the highest content of Proteobacteria and Firmicutes, and also contains a certain proportion of Desulfobacteria. When dietary fiber is added, the relative abundance of Actinobacteria increases, while the relative abundance of Desulfobacteria decreases, especially APS-1 and APS-2 greatly reduce the abundance of Desulfobacteria. Fig. 9 It can be seen that at the genus level, the relative abundance of Klebsiella, Streptococcus, Bifidobacterium, Lactococcus, Romboutsia, and Subdoligranulum increased significantly with dietary fiber intervention, APS-1 and APS-2 promoted the increase of Dialister, but inulin did not. In addition, the enrichment levels of bacteria of the above six genera of APS and APS-1 were comparable and better than APS-2, and the enrichment of Bifidobacterium and Lactococcus by APS and APS-1 was better than that of inulin. Compared with the blank group, the abundance of bacteria at the genus level of Escherichia-Shigella, Parasutterella, Citrobacter, Lachnoclostridium, Paeniclostridium, Phascolarctobacterium, Allisonella, Clostridium_sensu_stricto_1, Fournierella, and Colidextribacter in the APS, APS-1, APS-2, and inulin groups decreased. Compared with inulin, APS and APS-1 can more significantly downregulate the abundance of Citrobacter and Bilophila.
[0090] Depend on Fig.10Linear discriminant analysis (LDA) analysis of LEfSe and taxonomic cladogram analysis showed that the significantly enriched bacteria in the APS, APS-1, APS-2, and inulin groups were different. For example, APS significantly enriched the genus Lactococcus, APS-1 significantly enriched the genus Enterobacter that can degrade complex carbohydrates, and inulin significantly enriched the genus Streptococcus.
[0091] SCFA is the main fermentation product of polysaccharides metabolized by intestinal microorganisms and has many benefits to human health. Therefore, this example also measured the contents of seven SCFAs, namely, acetic acid, propionic acid, isobutyric acid, butyric acid, valeric acid, isovaleric acid, and caproic acid, in the culture medium after 24 hours of in vitro colonization of APS, APS-1, APS-2, and inulin. Fig.11 The results showed that compared with the blank group, the contents of acetic acid, propionic acid, butyric acid and valeric acid were significantly increased after adding carbon source. In addition, the APS-1 group increased more types of SCFA and increased the content compared with the APS and APS-2 groups. The contents of acetic acid, propionic acid and butyric acid in the APS-1 group were also significantly increased compared with the inulin group.
[0092] Overall, APS and the other two components increased the relative abundance of beneficial bacteria and reduced the abundance of potentially harmful bacteria, thereby improving the composition of the human intestinal microbiota, and the improvement effects of APS and APS-1 were more significant. Different APS components promoted the proliferation of different probiotics during the in vitro fermentation of intestinal bacteria, and may have obvious functional diversity in promoting disease prevention or reducing the risk of other negative health effects associated with these bacteria. It was also found that APS and the other two components can significantly increase the content of SCFA in the fermentation broth, and APS-1 has a better ability to regulate the production of SCFA by the flora.
[0093] Example 8
[0094] Dynamic distribution of APS-1 and APS-2 polysaccharides in mice
[0095] In order to clarify whether APS-1 and APS-2 can reach the intestine and be utilized by the flora after oral administration, an experiment was set up to observe their distribution in mice. First, the mice were given the prepared labeled fluorescent polysaccharides, and the mice were subjected to near-infrared fluorescence imaging detection at 0h, 1h, 2h, 4h and 6h using a small animal imaging system.
[0096] like Fig.12 As shown, the fluorescence images showed that the signal intensity of the whole mouse was mainly observed in the digestive tract. This result indicates that APS-1 and APS-2 after oral administration reach and accumulate in the digestive system, and most of the polysaccharides can resist degradation by saliva and gastric juice and reach the intestine.
[0097] like Fig.13 As shown, the average fluorescence intensity of APS-1 in the small intestine first increased, reached a maximum at 1 hour, and then decreased. Similarly, the average fluorescence intensity of APS-1 in the cecum and colon tended to be the highest at 2 hours, respectively, and the fluorescence intensity gradually weakened over time. The average fluorescence intensity of APS-2 in the small intestine did not show a significant increase after 1 hour. The average fluorescence intensity of APS-2 in the cecum reached a maximum at 1 hour, and the average fluorescence intensity in the colon reached a maximum at 2 hours, and the fluorescence intensity also gradually weakened over time.
[0098] The above results revealed that APS-1 and APS-2 were degraded in the intestine, but the overall average fluorescence intensity of APS-1 in the intestine was higher than that of APS-2. Combined with the fact that APS-1 was not degraded in simulated saliva, gastric juice and small intestinal juice, and APS-2 was slightly degraded in simulated saliva and gastric juice, the effects of APS-1 and APS-2 may be related to their utilization by intestinal flora, but APS-1 can better reach the intestine and be utilized by intestinal flora.
[0099] Example 9
[0100] Animal experiments on the improvement of colitis in mice after taking APS-1 and APS-2:
[0101] Fifty female C57BL / 6J mice (8 weeks old, 22 ± 2 g) were purchased from the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences (Lanzhou, China). The mice were housed under conditions of 23 ± 3 °C, 55 ± 15% relative humidity, 12 h light / 12 h dark cycle, and free access to standard feed and water. The animal experimental protocol was approved by the Ethics Committee of Lanzhou University (IACUC number: 2022-06-GDA-01). All animal experiments were performed in accordance with the ARRIVE guidelines and followed the Guide for the Care and Use of Laboratory Animals of the National Research Council of the United States.
[0102] After the mice adapted for one week, they were randomly divided into five groups, with 10 mice in each group. (1) Control group: The mice were given normal diet and water throughout the experiment, and were gavaged with PBS (200 mg / kg / day); (2) DSS group (induced enteritis model group): The mice were gavaged with PBS for 4 weeks, and from the 4th week, they were allowed to drink water containing 3.5% DSS (molecular weight 36000-50000Da, Ye Sen, China) freely. (3) APS+DSS group: The mice were gavaged with APS (200 mg / kg / day) for 4 consecutive weeks, and from the 4th week, they were allowed to drink water containing 3.5% DSS freely. (4) APS-1+DSS group: The mice were gavaged with APS-1 (200 mg / kg / day) every day for 4 consecutive weeks, and from the 4th week, they were allowed to drink water containing 3.5% DSS freely. (5) APS-2+DSS group: Mice were gavaged with APS-2 (200 mg / kg / day) for 4 consecutive weeks, and were allowed to drink water containing 3.5% DSS freely from the 4th week. Fig.14 Throughout the experiment, the body weight, fecal blood, and diarrhea severity of the mice were monitored, and the disease activity index (DAI) was evaluated based on these parameters.
[0103] Depend on Fig.15 , 16 and 17, compared with the DSS group, APS-1 treatment significantly reduced DSS-induced weight loss, decreased disease activity index (DAI) scores, and inhibited colon length shortening. In addition, APS-2 reduced the disease activity index and inhibited colon length shortening, but did not significantly reduce DSS-induced weight loss. Inflammatory cell infiltration, mucosal damage, and overall histological scores in the colon were significantly attenuated by APS-1 and APS-2 treatment.
[0104] Example 10
[0105] Assessment of inflammation levels in animals:
[0106] The present application also measured the inflammatory cytokines in the plasma and colon tissue of each group of mice in Example 9. The levels of IL-10, IL-6, TNF-α, and IL-1β in serum were evaluated using commercial kits from Shanghai Kexing Trading (Shanghai, China). The levels of IL-10, IL-6, TNF-α, IL-1β, MPO, Occludin, and ZO-1 in colon tissue were evaluated using ELISA test kits obtained from Shanghai Kexing Trading (Shanghai, China).
[0107] like Fig.18As shown in the results, the concentrations of IL-1β, IL-6, and TNF-α in serum of DSS-induced colitis were significantly increased, and the concentration of IL-10 was significantly decreased. However, the treatment with APS-1 and APS-2 significantly inhibited the increase of IL-1β, IL-6, and TNF-α in serum, and promoted the increase of IL-10. Similarly, APS-1 significantly inhibited the increase of IL-1β, IL-6, and TNF-α in colon tissue, and increased the content of IL-10, but APS-2 inhibited the increase of IL-1β and IL-6 concentrations in colon tissue, and promoted the increase of IL-10, but no significant difference was observed in TNF-α.
[0108] Collectively, these results suggest that both APS-1 and APS-2 can improve clinical colitis symptoms and colonic damage, but APS-1 has a more significant effect on DSS-induced colitis-related improvements.
[0109] Embodiment 11
[0110] Transmission electron microscopic observation and pathological analysis of tissue sections of colon tissues of each group of mice in Example 9
[0111] Fixed distal colon tissue was dehydrated in graded ethanol and xylene, embedded in paraffin, and sectioned at 4 μm thickness. It was then stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Alcian blue-periodic acid-Schiff (AB-PAS). Observations were performed using a Nikon Eclipse E100 microscope under bright field magnification of 200 times. H&E stained sections were evaluated histopathologically according to the scoring system shown in Table 2. Mucin area was calculated using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
[0112] Colon tissue was fixed with PBS containing 2.5% glutaraldehyde, fixed with 1% osmium tetroxide for 2 h, and then dehydrated in a graded series of ethanol. The tissue was resin infiltrated, embedded, and sectioned. Ultrathin sections were stained with uranyl acetate and lead citrate and then observed by transmission electron microscopy (TEM, Talos F200C).
[0113] Depend on Fig.19It can be seen that the results of PAS staining showed that mucus goblet cells were distributed in the colonic crypts of the control group, while the mucus goblet cells in the DSS-induced colitis mouse model group were almost completely destroyed. APS-1 and APS-2 had a protective effect on colonic mucus goblet cells. The goblet cells containing mucin in each group were calculated using ImageJ version 6.0, and the calculation results are shown in Table 3. It was found that supplementation of APS-1 and APS-2 could alleviate the goblet cell depletion caused by DSS, which was consistent with the results of H&E staining. The results of AB-PAS staining showed that APS-1 and APS-2 treatment significantly increased the glycoprotein content in the goblet cells on the surface of the colonic epithelium and the mucin content in the crypts. These results indicate that APS-1 and APS-2 can protect the intestinal mucus barrier by inhibiting mucus destruction and enhancing mucin secretion.
[0114] TEM images showed that DSS treatment shortened intestinal epithelial villi, destroyed brush borders, and disrupted tight junctions. APS-1 and APS-2 treatments improved epithelial structures and tight junctions between epithelial cells, and APS-1 more significantly reduced brush border disruption than APS-2. These results suggest that APS-1 and APS-2 can protect the intestinal mucus barrier by inhibiting goblet cell depletion, mucus disruption, and enhancing mucin secretion, and that APS-1 can more effectively attenuate DSS-induced damage to the mucosal barrier function.
[0115] Table 2 Histopathological scores
[0116]
[0117]
[0118] Table 3 Number of goblet cells containing mucin in each group (unit)
[0119] C M APS-1 APS-2 735 114 410 327 789 301 496 396 789 154 455 395 793 248 479 484 710 166 350 540 713 181 664 592
[0120] Example 12
[0121] DNA extraction and shotgun metagenomic sequencing
[0122] use DNA Stool Mini Kit (Qiagen, Hilden, Germany) was used to extract metagenomic DNA from the feces of each group of mice in Example 9. The purity and integrity of the extracted DNA were evaluated by 0.8% (w / v) agarose gel electrophoresis and the DNA was analyzed by NanoDrop 2000 (Novogene, Beijing, China) at OD 260 / 280The concentration was determined under 4% paraformaldehyde. Shotgun metagenomic sequencing was performed using the Illumina HiSeq6000 sequencing platform (Beijing Novogene Technology Co., Ltd.). DNA fragments of approximately 300 bp in length were prepared from the library, and these reads were trimmed using Sickle software, followed by removal of host DNA fragments.
[0123] like Fig. 20 As shown, according to the Simpson and Shannon index, the bacterial symbiotic richness and diversity in group M were significantly reduced compared with group C. After treatment with APS-1 and APS-2, the reduced α diversity in colitis mice was partially restored, and the recovery effect of APS-1 bacterial community diversity was better. Fig.21 Principal coordinate analysis (PCoA) showed that there were significant differences in the composition of the microbial communities among the four groups, which also preliminarily suggested that APS-1 and APS-2 may prevent ulcerative colitis by acting on different intestinal bacteria.
[0124] In order to further reveal the specific genus-level intestinal bacteria that metabolize APS-1 and APS-2, this application analyzed the top 25 genus-level bacteria in terms of abundance. Fig. 22 As shown, compared with group C, Allobaculum, Phocaeicola, Turicibacter, Faecalibaculum, Schaedlerella, Paraprevotella, and Blautia were significantly enriched in M. After treatment with APS-1 and APS-2, the abundance of Bacteroides, Oscillibacter, Roseburia, and Butyrivibrio was increased. Escherichia and Alistipes were more significantly enriched by APS-1, and Akkermansia, Parabacteroides, and Clostridium were mainly enriched by APS-2.
[0125] In order to further identify the species-level bacteria that metabolize APS-1 and APS-2, this application further analyzes the intestinal bacteria at the species level. Fig.23As shown, compared with the M group, APS-1 was enriched with Roseburia hominis, Bacteroides acidifaciens, etc., and APS-2 was enriched with Flintibacter sp.DSM 110149, Bacteroidescaecimuris, Oscillibacter sp.CU971, Akkermansia muciniphila, etc. 16 and 14 differential species were identified between the APS-1 group and the M group, and between the APS-2 group and the M group, respectively. After treatment with APS-1 and APS-2, the species-level bacteria related to dietary fiber metabolism, short-chain fatty acid production, and reduction of inflammation increased significantly, and the differential species between APS-1 and APS-2 were not the same. Bacterium 1xD42-87, Bacteroides caecimuris, Gallalistipes aquis granensis, Alistipes communis, Rikenella microfusus, Lachnospiraceae bacterium TWA4, etc. were the core species of the APS-1 group, especially multiple species of the genus Alistipes were enriched by APS-1, and Lachnospiraceae bacterium, Oscillibacter sp. CU971, Roseburia sp. CAG: 303, Subdoligranulum variabile, Murimonas intestini, etc. were the core species of the APS-2 group.
[0126] Embodiment 13
[0127] Determination of SCFAs in mouse colonic feces
[0128] Take 10 mg of colonic feces from each group of mice in Example 9, homogenize with 400 μL of 80% methanol, and centrifuge to remove protein. Add 150 μL of derivatization reagent to the supernatant and derivatize at 40°C for 40 minutes. Then homogenize the supernatant (190 μL) with 10 μL of mixed internal standard solution. Finally, inject into LC-MS / MS system for analysis to measure the content of 6 short-chain fatty acids in feces.
[0129] Ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) system (Vanquish TM Flex UHPLC-TSQAltis TM, Thermo Scientific, Germany) was used for quantitative analysis of short-chain fatty acids (SCFA). A Waters ACQUITY UPLC BEH C18 column (2.1×100 mm, 1.7 μm) was used for separation, and the column temperature was maintained at 40°C. The mobile phases were 10 mM ammonium acetate aqueous solution (solvent A) and acetonitrile:isopropanol (1:1) (solvent B), with a flow rate of 0.30 mL / min. The solvent gradient was set as follows: initial 25% B, 2.5 minutes; 25-30% B, 3 minutes; 30-35% B, 3.5 minutes; 35-38% B, 4 minutes; 38-40% B, 4.5 minutes; 40-45% B, 5 minutes; 45-50% B, 5.5 minutes; 50-55% B, 6.5 minutes; 55-58% B, 7 minutes; 58-70% B, 7.5 minutes; 70-100% B, 7.8 minutes; 100-25% B, 10.1 minutes; 25% B, 12 minutes.
[0130] The mass spectrometer was operated in negative multiple reaction mode (MRM) with the following parameters: ion spray voltage (-4500 V), sheath gas (35 psi), ion source temperature (550° C.), auxiliary gas (50 psi), and collision gas (55 psi).
[0131] like Fig.24 As shown in the figure, DSS significantly reduced the six SCFAs tested, APS-1 increased most of the SCFAs and significantly increased the concentrations of acetate, propionate, butyrate, isobutyrate and valerate, and APS-2 increased the concentrations of acetate, propionate and butyrate, but the difference in isovaleric acid between the groups was not significant. Overall, APS-1 and APS-2 can improve the intestinal flora imbalance induced by DSS, enrich SCFA-producing bacteria, and increase the content of SCFA in the colon, but it is worth noting that APS-1 is better than APS-2 in improving SCFA capacity.
[0132] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A use of astragalus polysaccharide as a potential prebiotic in the preparation of a medicament for preventing and / or treating ulcerative colitis, characterized in that: The molecular weight of the astragalus polysaccharide is ≤50KDa.
2. The use according to claim 1, characterized in that The molecular weight of the astragalus polysaccharide is less than 10KDa.
3. The use according to claim 2, characterized in that The preparation method of the astragalus polysaccharide comprises the following steps: (1) Soaking the astragalus powder in water, boiling and extracting to obtain an extract; (2) concentrating and cooling the extract, adding anhydrous ethanol, and performing alcohol precipitation to obtain a precipitate; (3) dissolving the precipitate in water, removing protein from the precipitate by enzymatic hydrolysis combined with the Sevage method, and collecting the supernatant; (4) adding anhydrous ethanol to the supernatant, collecting the precipitate and performing vacuum freeze-drying to obtain crude astragalus polysaccharide; (5) Dissolving crude astragalus polysaccharide in water to obtain a crude astragalus polysaccharide aqueous solution, and ultrafiltration of the crude astragalus polysaccharide aqueous solution; the ultrafiltration cutoff value is 50KDa and 10KDa; collecting the fractions with molecular weight <10KDa and 10KDa≤molecular weight≤50KDa.
4. The use according to claim 3, characterized in that The water content of the astragalus powder is 35% to 75%, and the particle size is less than 50 mesh; the mass volume ratio of the astragalus powder to water is 1g:15 to 25mL, and the soaking time is 12 to 24h; the extraction is performed 2 to 4 times, and the extraction time each time is 1 to 1.5h.
5. The use according to claim 4, characterized in that The concentration in step (2) is to concentrate to 1 / 2 to 1 / 3 of the original volume, and the concentration temperature is 90 to 100°C.
6. The use according to claim 5, characterized in that The amount of water added in step (3) is based on the complete dissolution of the precipitate; the enzymatic hydrolysis method uses papain, and the enzymatic activity of the papain is 100,000 U / g; the amount of papain added is 1-3 (w / v)%; the temperature of the enzymatic hydrolysis is 55-65°C, and the time is 4-6 hours.
7. The use according to claim 6, characterized in that The final concentration of the anhydrous ethanol after addition in step (2) and step (4) is 75-85 (v / v)%, the temperature of the alcohol precipitation is 1-4° C., and the time is 12-16 hours.
8. The use according to claim 7, characterized in that The vacuum freeze drying in step (4) is carried out at a temperature of -70 to -80°C, a vacuum degree of 10 MPa, and a time of 20 to 24 hours.
9. The use according to any one of claims 3 to 8, characterized in that: The concentration of the crude astragalus polysaccharide aqueous solution in step (5) is 200-300 g / L.
Citation Information
Patent Citations
Astragalus polysaccharides microecological regulator
CN102451221A
High-molecular-weight APS (astragalus polysaccharide) with anti-inflammatory activity as well as preparation method and application thereof
CN109265576A
Medium-molecular weight segment Astragalus polysaccharide and preparation method and application thereof
CN110218265A
Application of astragalus polysaccharide in preparation of drugs and health care products for regulating intestinal flora
CN110881662A
Interior air collecting device
KR102447952B1
Cited By
Astragalus homogeneous polysaccharide as well as preparation method and application thereof
CN121949589A
Radix astragali polysaccharide / oligosaccharide intestinal micro-ecological potency grading evaluation method and system
CN122791024A
